EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study

Dahham Alsoud iD, João Sabino, Denis Franchimont, Anneline Cremer, Julie Busschaert, François D'Heygere, Peter Bossuyt iD, Anne Vijverman, Séverine Vermeire, Marc Ferrante iD

Inflammatory Bowel Diseases · 05.12.2024 · 30 (12) · 2289-2296

DOI: 10.1093/ibd/izad315 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 12.01.2024. Verfasst von Dahham Alsoud und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Crohn Disease, Remission Induction. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As real-world data on risankizumab in patients with moderate to severe Crohn’s disease (CD) are scarce, we evaluated its effectiveness and safety in multirefractory Belgian patients.

Methods

Data from consecutive adult CD patients who started risankizumab before April 2023 were retrospectively collected at 6 Belgian centers. Clinical remission and response were defined using the 2-component patient-reported outcome. Endoscopic response was defined as a decrease in baseline Simple Endoscopic Score with ≥50%. Both effectiveness end points were evaluated at week 24 and/or 52, while surgery-free survival and safety were assessed throughout follow-up.

Results

A total of 69 patients (56.5% female, median age 37.2 years, 85.5% exposed to ≥4 different advanced therapies and 98.6% to ustekinumab, 14 with an ostomy) were included. At week 24, 61.8% (34 of 55) and 18.2% (10 of 55) of patients without an ostomy achieved steroid-free clinical response and remission, respectively. At week 52, these numbers were 58.2% (32 of 55) and 27.3% (15 of 55), respectively. Endoscopic data were available in 32 patients, of whom 50.0% (16 of 32) reached endoscopic response within the first 52 weeks. Results in patients with an ostomy were similar (steroid-free clinical response and remission, 42.9% and 14.3%, respectively). During a median follow-up of 68.3 weeks, 18.8% (13 of 69) of patients discontinued risankizumab, and 20.3% (14 of 69) of patients underwent CD-related intestinal resections. The estimated surgery-free survival at week 52 was 75.2%. No new safety issues were observed.

Conclusions

In this real-world cohort of multirefractory CD patients, risankizumab was effective in inducing both clinical remission and endoscopic response. Risankizumab was well tolerated with no safety issues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseRemission InductionHumansFemaleMaleAdultBelgiumRetrospective StudiesSeverity of Illness IndexMiddle AgedTreatment OutcomeAntibodies, MonoclonalPatient Reported Outcome Measures

Stichwörter der Autor:innen

Crohn’s diseasereal-worldrisankizumab

Substanzen

risankizumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
  • Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Gastroenterology, Erasme Hospital, Brussels, Belgium.
  • Laboratory of Experimental Gastroenterology, ULB, Brussels, Belgium.
  • Department of Gastroenterology, AZ Sint-Lucas, Brugge, Belgium.
  • Department of Gastroenterology, AZ Groeninge, Kortrijk, Belgium.

ORCID-Profile: Dahham Alsoud, Peter Bossuyt, Marc Ferrante

Zitieren

APA

Alsoud, D., Sabino, J., Franchimont, D., Cremer, A., Busschaert, J., D'Heygere, F., Bossuyt, P., Vijverman, A., Vermeire, S., & Ferrante, M. (2024). Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study. Inflammatory Bowel Diseases, 30(12), 2289-2296. https://doi.org/10.1093/ibd/izad315

Vancouver

Alsoud D, Sabino J, Franchimont D, Cremer A, Busschaert J, D'Heygere F, et al. Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study. Inflammatory Bowel Diseases. 2024;30(12):2289-2296. doi:10.1093/ibd/izad315

BibTeX
@article{Alsoud2024,
  author = {Alsoud, Dahham and Sabino, João and Franchimont, Denis and Cremer, Anneline and Busschaert, Julie and D'Heygere, François and Bossuyt, Peter and Vijverman, Anne and Vermeire, Séverine and Ferrante, Marc},
  title = {Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {12},
  pages = {2289--2296},
  doi = {10.1093/ibd/izad315}
}
Kostenlos starten →